#105Extended selection 101–500
Allogene Therapeutics
California
Cell and gene therapy
Manufacturing profile
Cell and gene therapy
Biopharma hub: California
Selection basis
The company is placed in positions 101–500 as a manufacturer, biotech, generics, advanced-therapy company or CDMO with practical relevance to the FUZKK utility catalog.
The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.
Representative manufacturing and QC chain
- 1Starting-material and cell-bank control
- 2Cell expansion or vector production
- 3Purification, concentration and formulation
- 4Identity, viability, potency and qPCR
- 5Sterility, endotoxin, environmental monitoring and chain of custody
Relevant FUZKK packages
Product/API utilities
Lumex — instrumental QC
LabEx — laboratory QC
Medical Devices — equipment and software lifecycle
Suggested first pilot
- Confirm one real product, method or recurring QC review.
- Record the instrument, export format and current specification.
- Select 3–7 utilities from the map above.
- Run a PASS/FAIL sample and agree the expected output.
- After user validation, expand to other products and sites.
Mapping boundary
The Top 500 is a FUZKK atlas priority rather than a single official revenue table. Inclusion in an FDA or industry source does not mean product approval, confirmation of a site's current status or actual use of FUZKK.
Methodology